Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to engineering cell therapies for patients with B-cell-driven autoimmune diseases. Headquartered in Emeryville, California, the company leverages CAR T-cell technology—traditionally used in oncology—to target and reset the immune system in autoimmune conditions. Its lead clinical asset, mivocabtagene autoleucel (miv-cel or KYV-101), is an autologous CD19-targeting CAR T-cell therapy undergoing Phase 2 trials for neuroimmunology and rheumatology indications, including stiff person syndrome, generalized myasthenia gravis, and lupus nephritis. Additionally, Kyverna is developing KYV-201, an allogeneic version of its CAR T-cell therapy, to potentially broaden patient access. The company aims to provide one-time treatments that eliminate the need for chronic immunosuppressants.
